Lynn Anne Bristol

Array ( [id] => 15395881 [patent_doc_number] => 10538585 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-21 [patent_title] => Anti-ANG2 antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 15/591600 [patent_app_country] => US [patent_app_date] => 2017-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37977 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15591600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16704382 [patent_doc_number] => 10954302 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Anti-PD-L1 antibodies [patent_app_type] => utility [patent_app_number] => 16/098479 [patent_app_country] => US [patent_app_date] => 2017-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 37105 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16098479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19354119 [patent_doc_number] => 12054550 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-06 [patent_title] => Bispecific antibodies targeting EGFR and HER2 [patent_app_type] => utility [patent_app_number] => 16/096698 [patent_app_country] => US [patent_app_date] => 2017-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 16 [patent_no_of_words] => 21316 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 309 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16096698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14227335 [patent_doc_number] => 20190125840 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => COMBINATION THERAPY COMPRISING AN INFLAMMATORY IMMUNOCYTOKINE AND A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL [patent_app_type] => utility [patent_app_number] => 16/093082 [patent_app_country] => US [patent_app_date] => 2017-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5777 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16093082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12212141 [patent_doc_number] => 09908936 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-06 [patent_title] => 'Antibody molecules to LAG-3 and uses thereof' [patent_app_type] => utility [patent_app_number] => 15/469096 [patent_app_country] => US [patent_app_date] => 2017-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 17 [patent_no_of_words] => 103094 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15469096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11757324 [patent_doc_number] => 20170204193 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'Antibody Fc Mutants with Ablated Effector Functions' [patent_app_type] => utility [patent_app_number] => 15/463716 [patent_app_country] => US [patent_app_date] => 2017-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 7905 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15463716 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12166150 [patent_doc_number] => 09884913 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-06 [patent_title] => 'Antibody molecules to TIM-3 and uses thereof' [patent_app_type] => utility [patent_app_number] => 15/462585 [patent_app_country] => US [patent_app_date] => 2017-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 35 [patent_no_of_words] => 90975 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15462585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11969916 [patent_doc_number] => 20170274070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'COMBINED THERAPEUTIC USE OF ANTIBODIES AND ENDOGLYCOSIDASES' [patent_app_type] => utility [patent_app_number] => 15/447622 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 16328 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15447622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14309713 [patent_doc_number] => 20190144560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => Monoclonal Antibodies That Specifically Recognize Canine DLA-DR Antigen and Their Uses [patent_app_type] => utility [patent_app_number] => 16/076801 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4013 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16076801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15054901 [patent_doc_number] => 10457739 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-29 [patent_title] => Anti-CEACAM5 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 15/446465 [patent_app_country] => US [patent_app_date] => 2017-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 23 [patent_no_of_words] => 38912 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15446465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15086405 [patent_doc_number] => 20190338013 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => Multi-Specific Molecules [patent_app_type] => utility [patent_app_number] => 16/079949 [patent_app_country] => US [patent_app_date] => 2017-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34709 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16079949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15102237 [patent_doc_number] => 10472419 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-12 [patent_title] => Antibody molecules to TIM-3 and uses thereof [patent_app_type] => utility [patent_app_number] => 15/432819 [patent_app_country] => US [patent_app_date] => 2017-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 35 [patent_no_of_words] => 78800 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15432819 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14639125 [patent_doc_number] => 10364295 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-30 [patent_title] => Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers [patent_app_type] => utility [patent_app_number] => 15/429276 [patent_app_country] => US [patent_app_date] => 2017-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 25440 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 153 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15429276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16141511 [patent_doc_number] => 10703818 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-07 [patent_title] => Human monoclonal antibodies against CD25 [patent_app_type] => utility [patent_app_number] => 15/420824 [patent_app_country] => US [patent_app_date] => 2017-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 19 [patent_no_of_words] => 28097 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15420824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16640916 [patent_doc_number] => 10918737 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-16 [patent_title] => Methods and pharmaceutical composition for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 16/073141 [patent_app_country] => US [patent_app_date] => 2017-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 15 [patent_no_of_words] => 15788 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16073141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16932479 [patent_doc_number] => 20210198368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => MULTISPECIFIC MOLECULES TARGETING CLL-1 [patent_app_type] => utility [patent_app_number] => 16/070501 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54969 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -60 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16070501 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11821862 [patent_doc_number] => 20170210799 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'ANTI-ROR1, ANTIBODIES, ROR1 X CD3 BISPECIFIC ANTIBODIES, AND METHODS OF USING THE SAME' [patent_app_type] => utility [patent_app_number] => 15/409630 [patent_app_country] => US [patent_app_date] => 2017-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 66246 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15409630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18428756 [patent_doc_number] => 11673966 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Monoclonal and humanized antibodies to a cancer glycopeptide [patent_app_type] => utility [patent_app_number] => 16/478833 [patent_app_country] => US [patent_app_date] => 2017-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 9 [patent_no_of_words] => 4984 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16478833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11954755 [patent_doc_number] => 20170258905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-14 [patent_title] => 'METHODS AND COMPOSITIONS FOR ENHANCING THE POTENCY OF SUPERANTIGEN MEDIATED CANCER IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 15/402888 [patent_app_country] => US [patent_app_date] => 2017-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 20758 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15402888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649506 [patent_doc_number] => 20170145407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'METHODS FOR INCREASING THE DIVERSITY OF MONOCLONAL ANTIBODIES PRODUCED AGAINST AN ANTIGEN' [patent_app_type] => utility [patent_app_number] => 15/401621 [patent_app_country] => US [patent_app_date] => 2017-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 14976 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15401621 [rel_patent_id] =>[rel_patent_doc_number] =>)